TH-302 5mg 5mg | Purity Not Available
Adooq Bioscience
TH-302 is a selectively targeting hypoxic regions of solid tumors hypoxia-activated prodrug.
More Information Supplier PageTH-302 is a selectively targeting hypoxic regions of solid tumors hypoxia-activated prodrug.
More Information Supplier PageTH-302 is a selectively targeting hypoxic regions of solid tumors hypoxia-activated prodrug.
More Information Supplier PageTH-302 is a selectively targeting hypoxic regions of solid tumors hypoxia-activated prodrug.
More Information Supplier PageSB-705498 is a potent, selective and orally bioavailable TRPV1 antagonist.
More Information Supplier PageSB-705498 is a potent, selective and orally bioavailable TRPV1 antagonist.
More Information Supplier PageSB-705498 is a potent, selective and orally bioavailable TRPV1 antagonist.
More Information Supplier PageSB-705498 is a potent, selective and orally bioavailable TRPV1 antagonist.
More Information Supplier PageSB-705498 is a potent, selective and orally bioavailable TRPV1 antagonist.
More Information Supplier PagePF 431396 is a dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor (IC50 values are 2 and 11 nM respectively).
More Information Supplier PageTOK-001 (Galeterone) is both an androgen receptor antagonist and CYP17A1 inhibitor.
More Information Supplier Page